The My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD publication covers some of the latest and practice-changing advances in the treatment for patients with chronic graft-vs-host disease following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.
December 01, 2021
Video
Yi-Bin Chen, MD, discusses risk factors for developing chronic graft-vs-host disease in patients who receive an allogeneic transplant.
December 01, 2021
Video
Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.
November 22, 2021
Article
Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses the variability in cGVHD presentation, key symptoms of the disease in patients with cancer, and how the field is navigating between available therapies.
November 19, 2021
Article
Corey S. Cutler, MD, MPH, FRCPC, discusses the diagnostic and treatment landscape of chronic graft-vs-host disease.
October 28, 2021
Article
As the armamentarium continues expanding for the treatment of patients with chronic graft-vs-host disease, research is ongoing to determine whether earlier integration of novel therapies, such as ruxolitinib, could yield better response rates for patients.
October 27, 2021
Article
Yi-Bin Chen, MD, discusses the nuances of diagnosing patients with cGVHD, the need for biomarkers to inform who is likely to develop the disease, the introduction of ruxolitinib and belumosudil to the paradigm, and future directions with novel strategies in the space.